The Effects Of Two Different Doses Of Simvastatin On Levels Of Serum Amyloid A And Serum Lipid In The Patients With UAP

Objective:Atherosclerosis was a chronic inflammatory intimal disease. Inflammatory outburst lay in local and system played a pivotal role in plaque rupture and ACS.Therefore, it is beneficial to apply stations in the early stage of UAP.Along with increasing experimental evidence implicating inflammatory and immune reactions in atherothrombosis, a wide range of circulating markers of inflammation predict cardiovascular risk in a variety of clinical settings.Finding a convenient and uninvasive check method which is used to judge the risk and prognosis in patients with unstable angina is very important,in order to early prevention and intervention. SAA is one of the acute phase reaction protein and sensitive inflammatory marker. SAA may be the more close relationship with the atherosclerosis. To observe the effect and difference to SAA, for indicator of inflammation,and blood lipid level in unstable angina patients treated with Simvastatin and discuss the impact of treatment of UAP using statin and evaluate the beneficial effects of Simvastatin on the inflammation. To observe the influence of two different doses simvastatin on serum SAA and lipid in patients of Unstable angina pectoris (UAP).Methods: 56 consecutive patients with UAP divided into two groups randomly: group1(n=21) was given 20mg/d simvastatin at night, group2(n=20) was given 40mg/d simvastatin,control group(n=18) was no lipid-lowering drugs.Coronary andiography was performed in all patients with UAP.Conventional therapy included aspirin,beta-blocker,angiotensin converting enzyme inhibitor, low-molecular-weight heparin.The control group were the medical staffs received physical health examination in our hospital. After 2 weeks of treatment, We compared serum levels of SAA and Lipids in blood. SAA was determined using enzyme-linked immunosorbent assay(ELISA)kits. All the data are expressed by±S.Comparisons in and between groups were analyzed by t-test,P-value<0.05(two-tailed)was considered statistically significant.Results:1.Baseline levels of TC,LDL-C,SAA were significantly higher in patients with UAP than those in control groups;2.The level of serum SAA is no difference among different stenoses numbers of lesions;3.No significant diffirence of lipid levels were observed in the Simvastatin 20mg group before and after treatment.But levels of lipid levels were decreased more significantly in the Simvastatin 40mg group than 20mg group (P<0.05);4. Compared to those before treatment, the level of levels of SAA decreased in the two group .There was significant difference after treatment (P<0.01). Comparing with 20mg/d simvastatin group there was relatively lower levels of SAA on the 2 day in the 40mg/d simvastatin group (P<0.01);5.One factor correlation analysis shows the level of SAA is not correlated the base concentration level of serum TC and LDL-C(r=0.133,P=0.329;r=0.196,P=0.148;P>0.O5 respectively);6. In two group the decrease of SAA had no correlation to the levels of TC and LDL-C decreased.Conclusion:1. The baseline serum levels of SAA was higher in the UAP group;2.The level of serum SAA is not correlated the base concentration level of serum lipid;3.The level of serum SAA is no difference among different stenoses numbers of lesions;4. The use of simvastatin decreased significantly level of SAA. It was associated with the dose of simvastatin.The level of SAA decreased had no correlation to the level of LDL-C and TC. The use of higher dose simvastatin in the patients of UAP may modulate lipids and benefit to atherosclerotic plaque stabilization.